Myomo Inc. (AMEX:MYO) is reporting third quarter financial results on Tuesday 10th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, MYO is expected to report 3Q20 loss of $ 1.05 per share from revenue of $ 1.17 million.
For the full year, analysts anticipate top line of $ 5.12 million, while looking forward to loss of $ 4.88 per share bottom line.
Previous Quarter Performance
Myomo Inc. reported loss for the second quarter of $ 1.12 per share, from the revenue of $ 0.86 million. The quarterly revenues declined 27.73 percent compared with the same quarter last year. Wall street analysts are predicting, MYO to report 2Q20 loss of $ 1.27 per share from revenue of $ 0.48 million. The bottom line results beat street analysts by $ 0.15 or 11.81 percent, at the same time, top line results outshined analysts by $ 0.38 million or 79.17 percent.
Stock Performance
Shares of Myomo Inc. traded up $ 0.13 or 2.82 percent on Monday, reaching $ 4.74 with volume of 98.30 thousand shares. Myomo Inc. has traded high as $ 4.75 and has cracked $ 4.58 on the downward trend
According to the previous trading day, closing price of $ 4.74, representing a 63.48 % increase from the 52 week low of $ 2.82 and a 88.48 % decrease over the 52 week high of $ 40.00.
The company has a market capital of $ 17.40 million and is part of the Healthcare sector and Medical Devices industry.
Conference Call
Myomo Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.myomo.com
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis used for the purpose of supporting a patients weak or deformed arm to enable and improve functional activities of daily living, ADLs, in the home and community. Its products are designed to help restore function in individuals with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders.
